| Clinical Takeaway | |||||||||||||||||||||
|
In 2006, researchers in Dallas described a woman with no working copies of a gene called PCSK9. Her LDL cholesterol was 14 mg/dL. In the paper's words, she was a "healthy, fertile college graduate."1
At the other extreme are children born with 2 faulty copies of the LDL receptor gene, the liver's main tool for clearing LDL from the blood. Untreated, their LDL can exceed 500 mg/dL; most develop overt atherosclerosis before age 20 and generally don't survive past 30, and heart attacks have been reported in early childhood.2
Nobody argues that the children's LDL is harmless, or that the woman's is dangerous. Every argument about cholesterol is about the space between them: whether the harm fades out somewhere in the middle, and whether lowering LDL there does any good.
In March, a documentary built around a now-retracted keto study premiered under the tagline "The Science Is Not Settled."3,4 A few weeks later I wrote that the cholesterol wars were over, and nothing I've covered since has reopened the question.
The myth that should die: that LDL is a marker rather than a cause, and the jury is still out. Causation can be tested, and LDL has faced 4 tests that could each have sunk it. Here's how each came out, with this year's trials in their place and the best objections answered at the end.
| Sponsored · Newsletter brought to you by MicroVitamin+ | |
|
|
| Why a multivitamin often turns your pee bright yellow | |
| A lot of multivitamins megadose, with some nutrients at ten times the daily value. MicroVitamin+ helps to fill the gaps in your diet, without the downsides of megadoses.* One scoop gives you the full multivitamin, 5 grams of creatine and collagen. | |
|
|
| Use code DRMIKE at checkout. | |
| I earn a commission on purchases made through this link or code. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. |
What it would take
In 1965, Austin Bradford Hill, who had helped show that smoking causes lung cancer, set out how to judge whether an association is causal.5 His viewpoints include a dose-response, consistency, plausibility, and the strongest of all, experiment: change the exposure and see whether the disease follows. None of them proves causation alone; together they can make the case.
For LDL, they become 4 predictions:
Born lower, less disease. People whose genes lower LDL from birth should get less heart disease, and people born higher should get more.
Any route works. Lowering LDL in randomized trials should prevent events, whatever does the lowering.
More, for longer, helps more. Benefit should grow with how far LDL falls and how long it stays down.
Other lipids don't substitute. Moving HDL or triglycerides while LDL particles stay put shouldn't help.
Test 1: Born lower, born higher
Genes are dealt at conception, before diet, income, or doctors can confound anything. That makes them a natural randomized trial, a method called Mendelian randomization, and nobody can cheat on adherence.
PCSK9 makes a protein that destroys LDL receptors. In the ARIC study, Black participants carrying variants that disable it had 28% lower LDL and 88% less coronary heart disease over 15 years; white participants with a milder variant had 15% lower LDL and 47% less disease.6 The woman with an LDL of 14 had no working copies at all.
A single gene could mislead, so in 2012 Brian Ference and colleagues pooled 9 LDL-lowering variants in 6 genes across 312,321 people. Each 1 mmol/L (39 mg/dL) of lifelong lower LDL went with 54.5% less coronary heart disease, whichever gene did the lowering: by the authors' calculation, about 3 times the benefit of a statin started later in life.7
Born higher runs the experiment in reverse. Familial hypercholesterolemia raises LDL from birth, and the children in the opening have its most extreme form. The same logic points to Lp(a), an LDL-like particle with an extra protein attached. It's the cholesterol you were born with, and its first outcome trial just came back neutral. That's in the ledger.
In 2019, Ference and colleagues asked what exactly those genes were lowering. LPL variants lower triglycerides; LDL receptor variants lower LDL cholesterol. Per 10 mg/dL lower ApoB, the protein that every LDL particle and its triglyceride-rich cousins carry, the 2 protected almost identically (odds ratios 0.771 and 0.773). Once ApoB was counted, triglycerides and LDL cholesterol added nothing.8
The cause is the particle. LDL cholesterol is how we usually count it, and LDL particles are most of what we're counting.9
Test 2: Lower it any way you like
If statins worked through some side effect, other ways of lowering LDL should fail. They don't, because nearly all of them pull the same lever: as I wrote in April, statins don't lower LDL; your liver does. Block cholesterol production (statins), absorption (ezetimibe), or receptor destruction (PCSK9 inhibitors), or make the liver spend cholesterol on bile (bile acid binders), and it responds the same way: more LDL receptors, fewer particles in the blood.
The cleanest proof is an operation. In POSCH, 838 heart attack survivors were randomized to diet alone or diet plus partial ileal bypass, surgery that stops the gut from reabsorbing bile acids, so the liver has to pull more cholesterol from the blood to replace them. No drug, so no drug side effect to take the credit. LDL fell 38%, and over nearly 10 years, coronary deaths plus nonfatal heart attacks fell 35% (82 vs 125); deaths from all causes were fewer, though not significantly.10
In 2016, Michael Silverman and colleagues lined up 49 trials of 9 kinds of LDL lowering against the LDL reduction each achieved. Per 1 mmol/L, statins cut major vascular events 23%. Non-statin therapies that work through the LDL receptor (diet, bile acid binders, ileal bypass, ezetimibe) cut them 25%, a difference well within chance (P = .72).11 A pill, a diet, and an operation landed on the same line.
| Lower risk per 1 mmol/L (39 mg/dL) lower LDL | ||||||
| The route doesn't matter. The years do. | ||||||
Statin trials · major vascular events
Non-statin trials · diet, bile acid binders, ileal bypass, ezetimibe
Genes, from birth · coronary heart disease
| ||||||
| Trial bars: statin and LDL-receptor trials from a 49-trial meta-regression, typically a few years long. Genetic bar: 9 variants in 6 genes, lifelong. Different designs and endpoints, so read the pattern, not the decimals.7,11 |
The newer drugs passed the same test in outcome trials: ezetimibe on top of a statin in IMPROVE-IT (32.7% vs 34.7% over 7 years),12 evolocumab in FOURIER (15% fewer events, at a median LDL of 30 mg/dL),13 and bempedoic acid in CLEAR Outcomes (13% fewer, in people who couldn't take statins).14
The European Atherosclerosis Society's consensus panel put the rule plainly: any way of lowering LDL particles should cut risk in proportion to the absolute reduction and how long it lasts, provided the drop in LDL cholesterol matches the drop in particle number and the drug has no harmful off-target effects.15 Remember those 2 conditions. They explain the failures in Test 4.
A settled theory also makes predictions. Enlicitide, an oral PCSK9 inhibitor, lowers LDL about 56% more than placebo on top of a statin.16 Its outcome trial hasn't reported. If LDL is causal, events should fall about as much as that LDL drop predicts, pill or shot.
Test 3: More, for longer
A cause should show a dose-response. In the Cholesterol Treatment Trialists' analysis of 26 statin trials and about 170,000 people, each 1 mmol/L reduction cut major vascular events by 22% (RR 0.78), with no threshold where the benefit stopped, even in people whose LDL was already below 2 mmol/L (77 mg/dL) on the less intensive or control regimen.17
Time is the other half of the dose, which is why the genetic bar is so much longer: genes lower LDL from birth, trials for about 5 years. Plaque is built from particles that cross into the artery wall and get stuck there, held by ApoB. The EAS's 2020 consensus says that retention "triggers a number of events that initiate and propagate lesion development."9 More particles, for more years, means more trapped. By simple multiplication, a 12-year-old with an LDL of 500 has had the exposure of a 50-year-old at 120.
This year's trials filled in the curve.
Lower. In 2020, Treat Stroke to Target tested goals rather than doses: after a stroke or TIA, an LDL goal under 70 mg/dL beat a range of 90 to 110 (HR 0.78).18 This year Ez-PAVE tested the next rung. In 3,048 Korean patients with established disease, a goal under 55 beat a goal under 70 (6.6% vs 9.7% at 3 years; HR 0.67), though achieved LDL differed by only 10 mg/dL.19 The CTT slope predicts about 6% for a gap that size, and the trial was open label with revascularization in its endpoint, so expect the true benefit to be smaller. The direction matches, and the 2026 ACC/AHA guideline now sets goals of under 55 for very-high-risk patients and under 70 for most others with established disease.20
Earlier. If exposure is what counts, waiting for the first heart attack makes no sense. VESALIUS-CV randomized 12,257 people with atherosclerosis or diabetes, but no prior heart attack or stroke, to evolocumab or placebo. Over a median of 4.6 years, first major events fell from 8.0% to 6.2% (HR 0.75).21 In the prespecified subgroup with diabetes and no known significant plaque, the hazard ratio was 0.69.22
Plaque starts long before risk scores notice. In REACT, 57.1% of 16,808 adults aged 18 to 70 with no known cardiovascular disease had it, rising from 8.7% of men aged 18 to 29 to 98.1% of men aged 60 to 70 (women: 6.7% to 91.9%). That climb is consistent with accumulating exposure. Among plaque-positive participants aged 40 to 69 without diabetes, SCORE2 called 1.9% high risk.23
The artery itself. FLOWPROMOTE randomized 104 patients with flow-limiting coronary disease to rosuvastatin plus ezetimibe (LDL 42.5 mg/dL) or atorvastatin (LDL 69.5). Over 18 months, total plaque fell 21% versus 14%, and noncalcified plaque shrank, by any amount, in 51 of 52 patients on the combination versus 39 of 51 on atorvastatin.24 The primary endpoint, CT-derived blood flow, was neutral, and the trial is small. But the plaque moved the way the outcome trials predicted.
And it takes time. AMUNDSEN drove median LDL to 16 mg/dL within 6 weeks of a heart attack, versus 56 on standard care, yet 1-year events were inconclusive (14.6% vs 15.4%; OR 0.94; 95% CI, 0.73 to 1.19).25 A benefit that accumulates over years barely registers in 12 months.
Test 4: Move the other lipids, leave the particles alone
This is the test that separates a cause from a bystander. If heart disease came from bad cholesterol numbers in general, raising HDL, the "good cholesterol," should protect. Observationally it looks like it does, with 38% lower heart attack risk per standard deviation of higher HDL.26 For nearly 2 decades, the drug industry bet on it.
Genetics answered first. A variant in the LIPG gene raises HDL from birth without changing other lipids, so if HDL were protective, carriers should have had 13% fewer heart attacks. They had 1% fewer, indistinguishable from none. A score built from 14 HDL-raising variants didn't protect either, while the matching LDL score more than doubled risk per standard deviation.26
The trials agreed. CETP inhibitors raise HDL dramatically, and 4 have completed outcome trials, in 73,479 patients:
| CETP inhibitors · 4 outcome trials | |||||||||||||||
| HDL soared. Events didn't follow it. | |||||||||||||||
| |||||||||||||||
| Niacin, which raises HDL another way, failed too: AIM-HIGH (HR 1.02) and HPS2-THRIVE (RR 0.96), the larger trial, with more serious side effects.31,32 |
Read the right-hand column. A 133% rise in HDL bought nothing. The only CETP inhibitor that helped, anacetrapib, cut events 9%, close to the roughly 10% that the CTT slope predicts from its 17 mg/dL drop in non-HDL cholesterol, by my arithmetic, with no sign that doubling HDL added anything.
Evacetrapib is the row skeptics quote: LDL cholesterol fell 31%, and events didn't budge. Here the 2 conditions from Test 2 apply. CETP inhibitors cut the cholesterol carried inside LDL particles more than the number of particles, so LDL cholesterol overstates what changed, and a 2017 genetic analysis found that, on a statin-like genetic background, CETP variants protect in proportion to ApoB, not LDL cholesterol.33 ACCELERATE also stopped at a median of 26 months. Torcetrapib failed the other condition, raising blood pressure and aldosterone. Count particles instead of cholesterol, and the paradox goes away.
Triglycerides got the same test. In PROMINENT, pemafibrate cut triglycerides 26% in 10,497 people with diabetes while ApoB rose 4.8%, and events didn't move (HR 1.03).34 In this year's ESSENCE imaging study of 468 people, olezarsen cut triglycerides 64%, remnant cholesterol 72%, and ApoB 16%, and at 12 months noncalcified plaque matched placebo.35 As the genetics predicted, lowering triglycerides without lowering ApoB doesn't protect. ESSENCE, which did lower ApoB, is the harder case, and it's in the ledger below.
REDUCE-IT is the exception people raise: icosapent ethyl cut events 25%.36 But its placebo was mineral oil, LDL rose about 11% in that arm with inflammatory markers climbing alongside, and the authors of its biomarker analysis call the mechanism of benefit uncertain.37 It's a contested trial, not a clean test of triglyceride lowering.
| The core claim |
| ApoB-containing particles, mostly LDL, cause atherosclerosis. Lower them by almost any route and events fall, roughly in proportion to how far and for how long. Change HDL or triglycerides without changing ApoB, and events don't follow. |
| Free · Cardiovascular Evidence Cheat Sheet | |
| LDL-C, ApoB, Lp(a), and the outcomes trials behind treatment decisions, with absolute event rates and linked sources, in 4 pages. | |
|
The best arguments against
A settled claim should survive its best objections. These are the 5 I hear most.
"Half of heart attack patients have normal LDL." True, and it supports the case. In a US registry of 136,905 hospitalizations for coronary disease, almost half the patients had an LDL under 100 mg/dL on admission, and only 21% had been taking a lipid-lowering drug.38 "Normal" describes the average American, not human biology: a 2004 review put normal LDL at 50 to 70 mg/dL for hunter-gatherers, healthy newborns, and wild primates, none of which develop atherosclerosis.39 In the PESA study, 49.7% of 1,779 middle-aged adults with no conventional risk factors had atherosclerosis, and LDL tracked it even at levels considered normal.40 Normal and safe are different numbers.
"It's inflammation, not cholesterol." Inflammation is real and treatable: canakinumab cut events 15% in CANTOS without lowering lipids, and colchicine cut them 31% in LoDoCo2.41,42 That makes it a second target, not a replacement, and much of a plaque's inflammation is the wall's response to LDL retained and modified there.9 This year's biggest bet on inflammation alone, ZEUS, silenced IL-6 in 6,376 people with atherosclerosis, kidney disease, and high hsCRP. Inflammatory markers fell; events didn't (17.6% vs 17.7% over a median of 33 months; HR 0.99; 95% CI, 0.88 to 1.11).43
"In older people, higher LDL means longer life." That pattern comes mostly from studies counting deaths from any cause, where serious illness lowers cholesterol and makes low LDL look dangerous. When Danish researchers followed 91,131 people aged 20 to 100, none with known atherosclerotic disease or diabetes and none on a statin, and counted heart attacks instead, risk rose with LDL in every age group. People aged 70 to 100 had the highest absolute risk and the lowest number needed to treat.44
"My calcium score is zero, so my LDL doesn't matter." A calcium score sees calcified plaque, not the soft plaque that comes first. In NATURE-CT, 205 adults with calcium scores of 100 or less, over half at zero, took no lipid-lowering drugs between 2 CT angiograms about 5 years apart, and median noncalcified plaque roughly doubled, from 27.5 to 53.5 mm³.45 It shares 2 weaknesses I held against KETO-CTA, no comparison group and AI plaque reads, so it shows what untreated plaque can do, not what causes it. Even KETO-CTA's own blinded reanalysis, still a preprint, found plaque growing over 1 year.46
"The absolute benefit is tiny." Over 5 years in a low-risk person, it can be. That's about trial length and baseline risk, not cause. In the first CTT meta-analysis, the same statin effect meant 48 fewer people per 1,000 with a major vascular event over about 5 years among those with coronary disease, and 25 per 1,000 among those without it.47 A 5-year trial measures a slice of a lifelong exposure; the genetics show what the whole exposure is worth.
| The honest ledger · what's still open | ||||||||||
|
| Speculation · extrapolation beyond the data |
| If LDL harm accumulates as exposure, the logical endpoint is treating the exposure, not waiting for the event. The 2026 guideline took a first step with a Class 2a option for adults 30 to 59 whose 10-year risk is low but whose LDL or 30-year risk is high. By one estimate, the new guideline makes about 103 million US adults eligible for lipid-lowering therapy, up from 65 million under the 2018 guideline.50 The next step would be treating by lifetime LDL burden alone, starting in the 20s or 30s, on the genetic logic that a modest reduction held for decades can match a large one started at 60. Generic statins already make that cheap. No trial has tested it, and none will report for decades. Until one does, this is a hypothesis built on genetics and arithmetic. |
What I'd take into clinic
Measure the right things. LDL or ApoB, plus Lp(a) at least once in every adult. A high Lp(a) is a reason to treat everything else harder.
Treat to a number. Under 55 mg/dL for very-high-risk patients with established disease and under 70 for the rest. In primary prevention, the guideline sets a goal under 70 once the calcium score reaches 100; for smaller plaque found on screening, the right target is still unsettled.20
Combine early. Statin plus ezetimibe from the start when the gap to goal is large. Stepwise care leaves most patients short: in AMUNDSEN's usual-care arm, 60% weren't at goal a year after their heart attack, despite 5 study visits.25
Don't let a zero end the conversation. A low risk score or a calcium score of zero describes short-term probability, not biology.
Rechallenge before charting intolerance. In SAMSON, 90% of the symptom burden on a statin also showed up on placebo.51 The pain is real; the attribution often isn't. If intolerance is confirmed, switch to a non-statin with outcome data instead of stopping.
I take a statin and ezetimibe myself. I explained why in "I'm 36. I'm a Physician. I Take a Statin Every Day."
The bottom line
LDL causes atherosclerotic heart disease. Genes that lower it from birth protect, trial after trial of lowering it prevents events in proportion to how far and how long, and drugs that moved HDL or triglycerides without moving ApoB particles didn't help. That's what settled looks like in medicine: not every question closed, but the open ones are about using the answer. How low, how early, and how to reach the people who need it. The science is settled. The care isn't.
| Reaching an LDL goal usually takes more than a single prescription and a single visit, and so does treating obesity. At Vineyard, our clinicians treat obesity and cardiometabolic risk together, including the lipid panel. See how Vineyard approaches obesity and cardiometabolic care → |
Following the latest GLP-1 clinical trials?
| Explore the trial tracker → |
Disclosure: The author is Chief Medical Officer of Vineyard, a telehealth obesity medicine practice. He is a consultant to Viking Therapeutics and provides research consulting to Novo Nordisk, which developed ziltivekimab (ZEUS). The REACT and FLOWPROMOTE studies were funded by the Novo Nordisk Foundation. This issue includes a paid sponsorship for MicroVitamin+, and the author earns a commission on purchases made through its link or code. This article is educational and is not individualized medical advice. Talk with your own clinician before making changes to your care.
| The archive · 2026 | ||||||||||||||||||||||||||||||||||
| Everything I've written on LDL and lipids, oldest first | ||||||||||||||||||||||||||||||||||
|
REFERENCES
1. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514-523. doi:10.1086/507488
2. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-2157. doi:10.1093/eurheartj/ehu274
3. The Cholesterol Code (2026), directed by Jennifer Isenhart [Internet]. Letterboxd [cited 2026 Oct 23]. Tagline. Available from: https://letterboxd.com/film/the-cholesterol-code/
4. Soto-Mota A, Norwitz NG, Manubolu VS, et al. Retraction notice to: Longitudinal data from the KETO-CTA study: plaque predicts plaque, ApoB does not. JACC Adv. 2026;5(5):102824. Notice dated March 11, 2026. doi:10.1016/j.jacadv.2026.102824
5. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295-300. doi:10.1177/003591576505800503
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013
7. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-2639. doi:10.1016/j.jacc.2012.09.017
8. Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364-373. doi:10.1001/jama.2018.20045
9. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. doi:10.1093/eurheartj/ehz962
10. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323(14):946-955. doi:10.1056/NEJM199010043231404
11. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289-1297. doi:10.1001/jama.2016.13985
12. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387-2397. doi:10.1056/NEJMoa1410489
13. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
14. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353-1364. doi:10.1056/NEJMoa2215024
15. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
16. Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide (CORALreef Lipids). N Engl J Med. 2026;394(6):529-539. doi:10.1056/NEJMoa2511002
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
18. Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke (Treat Stroke to Target). N Engl J Med. 2020;382(1):9-19. doi:10.1056/NEJMoa1910355
19. Lee YJ, Lee SJ, Kim JW, et al. Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease (Ez-PAVE). N Engl J Med. 2026;394(14):1365-1375. doi:10.1056/NEJMoa2600283
20. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016
21. Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in patients without a previous myocardial infarction or stroke (VESALIUS-CV). N Engl J Med. 2026;394(2):117-127. doi:10.1056/NEJMoa2514428
22. Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial. JAMA. 2026;335(16):1400-1407. doi:10.1001/jama.2026.3277
23. Bundgaard H, García-Lunar I, Kofoed KF, et al. Prevalence of silent atherosclerosis across adult life (REACT). N Engl J Med. Published online August 29, 2026. doi:10.1056/NEJMoa2609059
24. Mortensen MB, Iraqi N, Sand NPR, et al. Intensive vs more intensive lipid-lowering therapy and plaque regression in statin-naive patients: prespecified analyses from the FLOWPROMOTE randomized clinical trial. JAMA Cardiol. Published online October 30, 2026. doi:10.1001/jamacardio.2026.4788
25. Montalescot G, Ferrari E, Souteyrand G, et al. LDL cholesterol lowering with evolocumab before percutaneous coronary intervention for acute myocardial infarction: the AMUNDSEN randomized clinical trial. JAMA. Published online August 29, 2026. doi:10.1001/jama.2026.17302
26. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580. doi:10.1016/S0140-6736(12)60312-2
27. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events (ILLUMINATE). N Engl J Med. 2007;357(21):2109-2122. doi:10.1056/NEJMoa0706628
28. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome (dal-OUTCOMES). N Engl J Med. 2012;367(22):2089-2099. doi:10.1056/NEJMoa1206797
29. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease (ACCELERATE). N Engl J Med. 2017;376(20):1933-1942. doi:10.1056/NEJMoa1609581
30. HPS3/TIMI55-REVEAL Collaborative Group; Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217-1227. doi:10.1056/NEJMoa1706444
31. AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. doi:10.1056/NEJMoa1107579
32. HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. doi:10.1056/NEJMoa1300955
33. Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA. 2017;318(10):947-956. doi:10.1001/jama.2017.11467
34. Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk (PROMINENT). N Engl J Med. 2022;387(21):1923-1934. doi:10.1056/NEJMoa2210645
35. Marston NA, Bergmark BA, Prohaska TA, et al. Effect of APOC3 inhibition with olezarsen on coronary atherosclerosis: Essence-TIMI 73b imaging study. Circulation. 2026;153(20):1539-1548. doi:10.1161/CIRCULATIONAHA.126.080012
36. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792
37. Ridker PM, Rifai N, MacFadyen J, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation. 2022;146(5):372-379. doi:10.1161/CIRCULATIONAHA.122.059410
38. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111-117.e2. doi:10.1016/j.ahj.2008.08.010
39. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142-2146. doi:10.1016/j.jacc.2004.03.046
40. Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors (PESA). J Am Coll Cardiol. 2017;70(24):2979-2991. doi:10.1016/j.jacc.2017.10.024
41. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
42. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease (LoDoCo2). N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372
43. Ridker PM, Lincoff AM, Marx N, Navar AM, Sattar N, Tuttle KR, et al. Interleukin-6 inhibition with ziltivekimab for atherosclerotic disease. N Engl J Med. Published online November 7, 2026. doi:10.1056/NEJMoa2612126 (ZEUS; NCT05021835)
44. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020;396(10263):1644-1652. doi:10.1016/S0140-6736(20)32233-9
45. Aldana-Bitar J, Krishnan S, Ichikawa K, et al. NATURal history of coronary PlaquE on cardiac computed tomography in individuals without MACE or lipid-lowering therapy: NATURE-CT study. J Cardiovasc Comput Tomogr. 2026;20(4):375-381. doi:10.1016/j.jcct.2026.05.002
46. Budoff MJ, Kinninger A, Manubolu VS, et al. The impact of sustained LDL-C elevation on plaque changes: primary coronary plaque progression results from the Keto CTA Study [preprint, not peer reviewed]. medRxiv. January 16, 2026. doi:10.64898/2026.01.15.26343955
47. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278. doi:10.1016/S0140-6736(05)67394-1
48. Cho L, Nicholls SJ, Frndak S, Wolski K, Nordestgaard BG, Manning B, et al. Pelacarsen and cardiovascular outcomes in patients with high lipoprotein(a). N Engl J Med. Published online November 7, 2026. doi:10.1056/NEJMoa2610159 (Lp(a)HORIZON; NCT04023552)
49. Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619-627. doi:10.1001/jamacardio.2018.1470
50. Sidiq SA, Zhang GY, Abramov D, et al. Projected impact of 2026 ACC/AHA/Multisociety Dyslipidemia Guideline on lipid-lowering therapy eligibility based on Class 1 and 2a recommendations. J Clin Lipidol. 2026;20(9):2046-2050. doi:10.1016/j.jacl.2026.07.008
51. Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects (SAMSON). N Engl J Med. 2020;383(22):2182-2184. doi:10.1056/NEJMc2031173
Evidence-based obesity medicine, twice a week. No hype, no telehealth grifts.


